Long-term Benzodiazepine Treatment in Patients with Psychotic Disorders Attending a Mental Health Service in Rural Greece

ABSTRACT

Introduction: Long-term benzodiazepine (BZD) treatment in patients with mental disorders is widespread in clinical practice, and this is also the case of patients with schizophrenia, although the evidence is weak and BZD prescription is discouraged by guidelines and medical authorities. Data on BZD prescription are usually derived from national or regional databases whereas information on the use of BZD by patients with schizophrenia and related psychoses in general population-based samples is limited. Materials and Methods: Information for 77 patients with psychotic disorders who were regularly attending follow-up appointments with the multidisciplinary Mobile Mental Health Unit of the prefectures of Ioannina and Thesprotia, Northwest Greece, during 1-year period (2015) was obtained from our database. Results: From the total of 77 engaged patients, 30 (39%) were regularly prescribed BZDs in the long term, as part of their treatment regimen. Prescribed BZDs were mostly diazepam and lorazepam, in 43.3% of cases each. The mean daily dose of these compounds was 13 mg and 3.77 mg, respectively. Statistical analysis showed a correlation of long-term BZD use with the history of alcohol/substance abuse. Most patients were receiving BZD continuously for several years, and the mean dose was steady within this interval. Conclusions: A large proportion of patients with psychotic disorders were regularly prescribed BZD in long term. It appears that when BZDs are prescribed for some period in the course of a psychotic disorder, their use commonly exceeds the recommended interval and then becomes a regular part of the chronic treatment regimen. Future research should address the factors that may be related to the long-term BZD use by patients with psychotic disorders. Interventions for the reduction of regular BZD prescription should target the primary care setting and all those who treat first episode patients.

KEYWORDS:

Benzodiazepines - community mental health services - rural areas - schizophrenia - substance abuse

• REFERENCES

• 1 British Medical Association. Royal Pharmaceutical Society of Great Britain. British National Formulary. London: BMJ Group and Pharmaceutical Press; 2012
• 2 Kurko TA, Saastamoinen LK, Tähkäpää S, Tuulio-Henriksson A, Taiminen T, Tiihonen J. et al. Long-term use of benzodiazepines: Definitions, prevalence and usage patterns – A systematic review of register-based studies. Eur Psychiatry 2015; 30: 1037-47
• 3 Huerta C, Abbing-Karahagopian V, Requena G, Oliva B, Alvarez Y, Gardarsdottir H. et al. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: A cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiol Drug Saf 2016; 25 Suppl (Suppl. 01) 56-65
• 4 Längle G, Steinert T, Weiser P, Schepp W, Jaeger S, Pfiffner C. et al. Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment. Acta Psychiatr Scand 2012; 125: 372-81
• 5 Clark RE, Xie H, Brunette MF. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry 2004; 65: 151-5
• 6 Wu CS, Lin YJ, Liu SK. Benzodiazepine use among patients with schizophrenia in Taiwan: A nationwide population-based survey. Psychiatr Serv 2011; 62: 908-14
• 7 Kim HY, Lee HW, Jung SH, Kang MH, Bae JN, Lee JS. et al. Prescription patterns for patients with schizophrenia in Korea: A focus on antipsychotic polypharmacy. Clin Psychopharmacol Neurosci 2014; 12: 128-36
• 8 Vares M, Saetre P, Strålin P, Levander S, Lindström E, Jönsson EG. Concomitant medication of psychoses in a lifetime perspective. Hum Psychopharmacol 2011; 26: 322-31
• 9 Baldwin DS, Aitchison K, Bateson A, Curran HV, Davies S, Leonard B. et al. Benzodiazepines: Risks and benefits. A reconsideration. J Psychopharmacol 2013; 27: 967-71
• 10 Fontanella CA, Campo JV, Phillips GS, Hiance-Steelesmith DL, Sweeney HA, Tam K. et al. Benzodiazepine use and risk of mortality among patients with schizophrenia: A retrospective longitudinal study. J Clin Psychiatry 2016; 77: 661-7
• 11 Nykänen S, Puska V, Tolonen JP, Salo H, Isohanni M, Koponen H. et al. Use of psychiatric medications in schizophrenia and other psychoses in a general population sample. Psychiatry Res 2016; 235: 160-8
• 12 Peritogiannis V, Mantas C, Alexiou D, Fotopoulou V, Mouka V, Hyphantis T. The contribution of a mobile mental health unit to the promotion of primary mental health in rural areas in Greece: A 2-year follow-up. Eur Psychiatry 2011; 26: 425-7
• 13 Peritogiannis V, Tatsioni A, Menti N, Grammeniati A, Fotopoulou V, Mavreas V. Treatment engagement of psychotic patients with a mobile mental health unit in rural areas in Greece: A five-year study. Schizophr Res Treatment 2013; 2013: 613956
• 14 Peritogiannis V, Tatsioni A, Manthopoulou T, Mavreas V. Mental healthcare for older adults in rural Greece. Int Psychogeriatr 2016; 28: 698-700
• 15 Sim F, Sweetman I, Kapur S, Patel MX. Re-examining the role of benzodiazepines in the treatment of schizophrenia: A systematic review. J Psychopharmacol 2015; 29: 212-23
• 16 Rigg KK, Ford JA. The misuse of benzodiazepines among adolescents: Psychosocial risk factors in a national sample. Drug Alcohol Depend 2014; 137: 137-42
• 17 Dell’osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry 2013; 28: 7-20
• 18 Brunette MF, Noordsy DL, Xie H, Drake RE. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv 2003; 54: 1395-401
• 19 Ziller EC, Anderson NJ, Coburn AF. Access to rural mental health services: Service use and out-of-pocket costs. J Rural Health 2010; 26: 214-24
• 20 Semansky R, Willging C, Ley DJ, Rylko-Bauer B. Lost in the rush to national reform: Recommendations to improve impact on behavioral health providers in rural areas. J Health Care Poor Underserved 2012; 23: 842-56
• 21 Crebbin K, Mitford E, Paxton R, Turkington D. Drug and alcohol misuse in first episode psychosis: An observational study. Neuropsychiatr Dis Treat 2008; 4: 417-23
• 22 Zhornitsky S, Rizkallah E, Pampoulova T, Chiasson JP, Lipp O, Stip E. et al. Sensation-seeking, social anhedonia, and impulsivity in substance use disorder patients with and without schizophrenia and in non-abusing schizophrenia patients. Psychiatry Res 2012; 200: 237-41
• 23 Peritogiannis V. Sensation/novelty seeking in psychotic disorders: A review of the literature. World J Psychiatry 2015; 5: 79-87
• 24 Vicens C, Bejarano F, Sempere E, Mateu C, Fiol F, Socias I. et al. Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: Cluster randomised controlled trial in primary care. Br J Psychiatry 2014; 204: 471-9
• 25 Thornicroft G, Semrau M, Alen A, Drake RE, Ito H, Mari J. et al. editors Community Mental Health: Putting Policy into Practice Globally. New York, USA: Willey-Blackwell; 2011
• 26 Peritogiannis V, Mantas C, Tatsioni A, Mavreas V. Rates of first episode of psychosis in a defined catchment area in Greece. Clin Pract Epidemiol Ment Health 2013; 9: 251-4
• 27 Verma SK, Subramaniam M, Chong SA, Kua EH. Substance abuse in schizophrenia. A Singapore perspective. Soc Psychiatry Psychiatr Epidemiol 2002; 37: 326-8